P1615: Aspects of the Therapy Selection for Immune Thrombocytopenia in Children

Abstract

Immune thrombocytopenia incidence ranges from 1.6 to 5.6 per 100,000 per year. The level of platelets requiring immediate initiation of therapy is a debatable issue in each case. The choice of the optimal regimen for both the first and second lines of ITP therapy remains an urgent problem. The treatment of chronic continuously relapsing forms of the disease is of particular difficulty.